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Abstract
The architecture and compartmentalization of the kidney
has stimulated the development of an array of micro-
techniques to study the functional differences between
the distinct nephron segments. With the vast amounts of
genomic sequence data now available, the groundwork
has been laid for a comprehensive characterization of the
molecular pathways defining the differences in nephron
function. With the development of sensitive gene expres-
sion techniques the tools for a comprehensive molecular
analysis of specific renal microenvironments have been
provided: Quantitative RT-PCR technologies now allow
the analysis of specific mRNAs from as little as single
microdissected renal cells. A more global view of gene
expression regulation is a logical development from the
application of large scale profiling techniques. In this
review, we will discuss the power and pitfalls of these
approaches, including their potential for the functional
characterization of nephron heterogeneity and diagnos-
tic application in renal disease.
Copyright © 2002 S. Karger AG, Basel
Introduction
Recent developments in molecular biology offer new
opportunities for experimental and clinical medicine.
With the completion of the draft sequence of the human
genome the entire human genetic code is being deci-
phered [1, 2]. In addition, the genomes of laboratory ani-
mals such as mice and rats will be available in the near
future. The integration of genomic information into bio-
logical function will be a major challenge for the biomedi-
cal community. A comprehensive analysis of the mRNA
and protein expression in health and disease is considered
to be an essential next step in this process. Current techni-
cal advances now allow a global analysis of the regulatory
pathways active in a tissue or disease process [3].
The most promising immediate clinical application for
patient care is the identification of mRNA expression pat-
terns that help to characterize pathophysioloical phenom-
enon in diseased organs and their correlation with the
diagnosis, prognosis and responsiveness to the different
available treatments [4–6]. To date the most conclusive
information available for diagnostic and therapeutic deci-
sions in clinical nephrology is the analysis of the affected
organ by fine needle biopsy. Biopsy material is analyzed
primarily by histology [7]. The quantitative measurement
of mRNA levels encoding functionally relevant molecules
will add important information to this powerful diagnos-
tic procedure in nephrology [8, 9].
Nephron Segment Specific Gene Expression
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Diverse studies have evaluated gene expression in
experimental kidney diseases, in renal cell culture studies
and, to some degree, in human renal disease. These stud-
ies have identified – among others – a large number of
cytokines, growth factors, chemokines and mediators of
inflammation as contributing to renal failure. To simulta-
neously determine a wide range of mRNA molecules in
microdissected tissues should further facilitate the charac-
terization of nephron segment specific regulatory net-
works.
This review describes the methods currently available
for nephron segment specific gene expression analysis, the
initial results obtained with these techniques, and the
major obstacles often encountered.
Obtaining Nephron Segments Suitable for Gene
Expression Analysis
The analysis of nephron segment specific gene expres-
sion was simplified with the discovery of the polymerase
chain reaction in the late 1980s. The nephrology commu-
nity was quick to adapt this technique to the specific
needs of the field [10–12]. Procedures were established to
obtain renal tissue from experimental animals and regula-
tory networks were delineated along the nephron at the
molecular level (see below and [13]).
Early on the translation of this approach to the analysis
of human renal biopsy material was evaluated [14]. To
obtain the necessary human renal biopsy tissue, technical
and ethical considerations had to be taken into account.
Renal biopsy is still an invasive procedure with a risk of
gross hematuria of about 5–9%, need for blood transfu-
sion of 0.1–3%, and nephrectomy of 0.02–0.05% [15].
Thus, any experimental protocol introduced must not
interfere with the diagnostic evaluation of the renal biop-
sy. Therefore, sufficient tissue for clinical diagnosis has to
be sampled, i.e. two biopsy cores of sufficient diameter
and length [16]. Although former studies analyzed mRNA
from an additional biopsy core [17, 18], new techniques
have increased the sensitivity of the measurements allow-
ing quantification of dozens of mRNA templates from
just 10% of one biopsy core [19]. Examination of both
cores under a stereo-microscope in the biopsy suite offers
a reliable approach to determine whether sufficient tissue
for diagnostic and research purposes has been sampled. In
a current multicenter study separation of 10% of a biopsy
core and mRNA-protected storage has not led to signifi-
cant interference with routine diagnostics [19].
An alternative approach is to study gene expression on
formaldehyde fixed, paraffin embedded tissues after com-
pletion of all necessary routine diagnostic evaluations.
Combined with laser microdissection, this new methodol-
ogy should enable retrospective mRNA analysis on neph-
ron segments even after years of storage [20, 21]. As a fur-
ther advantage this approach allows the selection of a
defined histological structure for gene expression evalua-
tion. Correlation of the mRNA expression profile with the
clinical course adds additional power to this analysis. A
major limitation of this technique is the low amount of
mRNA that can be harvested from a fixed tissue specimen
thus limiting the potential number of genes for analysis
[20].
Addressing Nephron Segment Heterogeneity
The kidney consists of more than 20 different cell types
and represents an organ of high functional complexity.
As a consequence, a wide array of techniques, including
micropuncture, microperfusion and microenzymatic
analysis of nephron segments have been developed for
experimental analysis [22]. The complex architecture of
the kidney makes the dissection of nephron segments
prior to gene expression analysis a crucial step in many
analyses. In diseased kidneys mRNA expression is often
differentially regulated in discreet nephron segments [23].
As a consequence, studies using whole kidney lysates
often are confounded by a large variation in the expres-
sion levels obtained.
Two techniques have been developed for separation of
nephron segments:
As an extension from microtechniques, the manual
microdissection of murine glomeruli has allowed the anal-
ysis of glomerular-specific gene expression [10, 12, 13].
This technique has been successfully transferred to hu-
man renal tissue [14] and was employed in several studies
[17, 24–27]. Microdissection and subsequent gene expres-
sion analysis of tubular nephron segments has also been
reported [28–30]. The manual skill and time required for
microdissection has limited the general application of this
technique. A further problem with this approach is the
loss of mRNA integrity during microdissection. This will
be addressed in more detail below.
In recent years the use of laser microdissection has
enabled the separation of nephron segments in frozen and
fixed sections [20, 31–33]. Using renal tissue section areas
of interest can be harvested for expression analysis via
laser capture microdissection, manual harvesting with mi-
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Fig. 1. Strategy for mRNA expression analysis on human biopsies in the multicenter setting. Immediately after renal
biopsy, 10% of the two cores are separated and stored in RNase inhibitor. Under a stereo microscope glomeruli and
tubulo-interstitium are separated by manual microdissection. The tissue can be stored for several years in RNase
inhibitor. The gene expression analysis is performed by real-time RT-PCR or cDNA arrays.
Biopsy Dissection Storage Analysis
cromanipulators or laser beam catapulting. These tech-
niques require less manual dexterity and allow staining of
the tissue for a clear delineation of the regions of interest.
However, mRNA yield can be as much as two order of
magnitudes lower as compared to manual microdissection
of intact nephron segments [own unpubl. observation].
Maintaining Intact mRNA Templates
A central challenge in mRNA analysis is the inherent
instability of the mRNA templates, particularly if materi-
al is to be obtained from clinical specimens. Like other
tissues, the kidney is rich in RNases that induce a rapid
degradation of mRNA. Several strategies have been em-
ployed to secure the template integrity for analysis:
Renal tissue can be immediately snap-frozen in liquid
nitrogen and subsequently stored at –80°C. This has been
effective in maintaining intact mRNA for months to years
[34].
To preserve mRNA during the manual microdissec-
tion of nephron segments the RNase inhibitor vanadyl
ribonucleoside complex was introduced by Moriyama et
al. and served as the standard protocol for subsequent
studies [10, 14]. With this approach the tissue still had to
be microdissected directly after harvesting at 4°C, snap-
frozen and stored at –80°C, significantly complicating
the application in a clinical setting.
The new classes of RNase inhibitors such as RNAlater
(Ambion) allows preservation of RNA even at room tem-
perature for several hours [19]. This gives a convenient
time window for the processing of the material. Using this
approach renal tissue and RNA has been shown to remain
intact at –20°C for more than three years [own unpubl.
observation]. After storage the nephron segments can still
be manually microdissected and the tissue remains suit-
able for immunohistochemical analysis [35]. This ap-
proach consistently allows high RNA preservation on
microdissected renal biopsies (fig. 1) [19].
Optimizing RNA Yield
Using minimal tissue amounts as starting material,
optimal RNA recovery is mandatory. In addition, all the
cell types present in a nephron segment, such as a glomer-
ulus, have to be lysed for RNA recovery. Initially, micro-
dissected samples were permeabilized with Triton X [10]
followed by direct reverse transcription of the obtained
whole tissue lysate (in-situ RT). This protocol gave higher
yields than an acid phenol based RNA extraction of the
microdissected glomeruli [14]. Recently, a silica gel based
RNA isolation was shown to be superior to in situ RT for
tubular-interstitial and glomerular samples [19, 34]. RNA
isolation also decreased the amount of contaminating
genomic DNA and can, if required, be combined with
removal of genomic DNA by DNase digestion.
Increasing Sensitivity of RNA Quantification
The low amount of available mRNA templates from
small tissue compartments, such as microdissected neph-
ron segments, requires the application of detection tech-
Nephron Segment Specific Gene Expression
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Fig. 2. mRNA quantification on microdissected single podocytes by real-time RT-PCR. After microdissection of a
glomerulus a single podocyte can be harvested using a patch-clamp set-up (insert). The single cell is lysed by freeze-
thaw steps and the RNA reverse transcribed. Quantification of cDNA is performed using real-time RT-PCR.
Dissection Cell isolation Storage Analysis
niques with extreme sensitivity. To this end, two ap-
proaches have been developed:
First, real time RT-PCR combines excellent sensitivity
with quantification by the direct determination of ampli-
con numbers after each PCR cycle [36, 37]. Microtiter
based assay formats allow for semi-automatization of the
quantification procedure. This method has made it possi-
ble to scale down the assays up to the level of a single
microdissected cell (fig. 2) [38, 39].
Oligonucleotide or cDNA arrays offer parallel quanti-
tative mRNA investigation of hundreds or thousands of
genes. A compelling alternative. However, the minimal
amount of starting material is currently F1 Ìg total RNA.
Sufficient RNA is easily accessible from kidneys of ani-
mal models [40] or nephrectomies [41]. For biopsy stud-
ies, an entire human renal biopsy has be used for the sudy
[42]. To obtain sufficient RNA from nephron segments a
considerable amount of starting material has to be gener-
ated, i.e. by differential sieving techniques. An additional
option would be to analyze microdissected nephron seg-
ments using cRNA that has been generated by RNA
amplification prior to array analysis. Several protocols for
the ‘linear amplification’ of cRNA have been developed
for use with laser microdissected tissue other than kidney
[43, 44]. The more than 1,000-fold amplification efficien-
cy of these protocols can generate sufficient cRNA for the
labeling reactions and array hybridizations. However, the
critical issue of the linearity of the amplification, i.e.
maintaining the different expression ratios between the
diverse mRNA populations, is still a matter of conjec-
ture.
Addressing the Focal Nature of Renal Disease
In renal disease, most processes affect the kidney in a
focal manner and microdissected samples of a renal biop-
sy presenting only a small fraction of the kidney are prone
to sample bias. In experimental studies, the sample error
can be addressed by obtaining large numbers of the
respective nephron segments from the same animal [23,
30]. In human biopsy studies, a comprehensive analysis of
an adequate number of diseased kidneys in each diagnos-
tic category is required.
Currently, two approaches appear to be feasible:
Prospective multicenter studies obtaining designated
material for molecular studies may generate sufficient
numbers of nephron segments in a central renal biopsy
depository [45]. Depending on the study design (see
above), adequate amounts of high-quality mRNA for
screening approaches can also be gathered (fig. 1).
Access to mRNA obtained from formalin fixed paraf-
fin embedded renal biopsy specimen will allow for retro-
spective studies on archival tissue (see above).
Outlook
A variety of animal models are currently being evaluat-
ed by nephron segment specific gene expression analysis.
Comprehensive material and clinical data from patient
populations are being generated for the study of human
disease (fig. 1).
Messenger RNA expression screening experiments on
human glomeruli have already identified novel regulatory
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Fig. 3. Strategy for nephron segment specific
molecular analysis. Gene expression of spe-
cific nephron segments is studied as given in
the text. The expression profiles (right) can
be analyzed in respect to the given experi-
mental or clinical data and histology find-
ings (left). Bioinformatic analysis aids in
identifying disease-specific molecular path-
ways, i.e. by displaying complex expression
pattern in graphical format (right) and by
definition of similarities between samples
(cluster dendrogram; left). Regulation of rel-
evant expression profiles has to be con-
firmed with an independent approach, i.e.
real-time RT-PCR (left) or immunohistology
(right). Thereafter, the molecular pathways
can be studied in detail using cell culture
studies or animal models.
Analysis:
Clinical data
Histology
Expression data
Bioinformatics:
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pathways active in renal disease [38, 46]. After evaluation
in in vitro and in vivo systems (fig. 3), these molecules
offer new diagnostic tools and also potential candidate
genes for therapeutic intervention. As sufficient numbers
of renal samples and clinical data become available, a
comprehensive expression analysis of renal biopsies will
allow a more global view of the regulatory mechanism
activated in human renal disease. Data mining tools are
being developed to display the complex expression pat-
terns, to identify coregulated genes [47] and to dissect
underlying transcriptional programs [48] (fig. 3).
The gene expression profiles may also be of use for
molecular diagnostic information to supplement the mod-
ern pathological procedures [8, 49]. This approach has
already been applied to the characterization of biopsy
material obtained in oncology and hematology [4–6, 50,
51]. As gene expression profiles are a direct consequence
of transcriptional programs, they have the potential to
allow a more functional categorization of renal disease
based on regulatory networks, rather than the descriptive
classification used to date. If a stratification of diseases
based on common molecular pathways can improve diag-
Nephron Segment Specific Gene Expression
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nostic impact regarding outcome and response to treat-
ment remains to be determined.
Focussing the power of molecular analysis on specific
nephron segments should provide a lot of answers, but
certainly will give raise to many new questions. Exciting
times ahead for the renal research community.
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